株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ケロイド : パイプライン分析

Keloids - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 257827
出版日 ページ情報 英文 49 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
ケロイド : パイプライン分析 Keloids - Pipeline Review, H2 2015
出版日: 2015年09月09日 ページ情報: 英文 49 Pages
概要

ケロイドとは、皮膚が創傷から回復した後に瘢痕組織が過剰に増殖する、という疾患です。主な症状として、皮膚が肉色(赤・ピンクなど)となる、こぶ(結節)が大量に発生する、皮膚の硬直化、衣類などが擦れた際に痒みを感じる、傷つきやすくなっている、といったことが挙げられます。主なリスク要因には年齢や家族歴などが上げられます。主な治療法として、コルチコステロイドや放射線治療、外科摘出手術、シリコンゲル、膏薬などがあります。

当レポートでは、世界各国でのケロイド治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

ケロイドの概要

治療薬の開発

  • ケロイド向けパイプライン製品:概要
  • ケロイド向けパイプライン製品:比較分析

各企業で開発中のケロイド治療薬

大学/研究機関で研究中のケロイド治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

ケロイド治療薬:開発中の製品の一覧(企業別)

ケロイド治療薬:研究中の製品の一覧(大学/研究機関別)

ケロイド治療薬の開発に従事している企業

  • RXi Pharmaceuticals Corporation
  • Vida Therapeutics Inc.

ケロイド:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • CIGB-128
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • CM-101
  • koebnerisin
  • psoriasin
  • RXI-109
  • V-2248
  • VTI-3000 Series

ケロイド治療薬:パイプライン製品の最新動向

ケロイド治療薬:開発が休止状態の製品

ケロイド治療薬:開発が中止された製品

ケロイド関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7138IDB

Summary

Global Markets Direct's, 'Keloids - Pipeline Review, H2 2015', provides an overview of the Keloids's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Keloids, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Keloids and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Keloids
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Keloids and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Keloids products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Keloids pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Keloids
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Keloids pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
    • Keloids Overview
  • Therapeutics Development
    • Pipeline Products for Keloids - Overview
    • Pipeline Products for Keloids - Comparative Analysis
  • Keloids - Therapeutics under Development by Companies
  • Keloids - Therapeutics under Investigation by Universities/Institutes
  • Keloids - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Keloids - Products under Development by Companies
  • Keloids - Products under Investigation by Universities/Institutes
  • Keloids - Companies Involved in Therapeutics Development
    • RXi Pharmaceuticals Corporation
    • Vida Therapeutics Inc.
  • Keloids - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CIGB-128 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CM-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • koebnerisin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • psoriasin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXI-109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-2248 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VTI-3000 Series - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Keloids - Recent Pipeline Updates
  • Keloids - Dormant Projects
  • Keloids - Discontinued Products
  • Keloids - Product Development Milestones
    • Featured News & Press Releases
      • Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology
      • Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study
      • Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders
      • Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period
      • Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision
      • Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109
      • Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Keloids, H2 2015
  • Number of Products under Development for Keloids - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Keloids - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
  • Keloids - Pipeline by Vida Therapeutics Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Keloids Therapeutics - Recent Pipeline Updates, H2 2015
  • Keloids - Dormant Projects, H2 2015
  • Keloids - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Keloids, H2 2015
  • Number of Products under Development for Keloids - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top